Search - tctmd.com

Displaying 1 - 20 of 31

Sort: Relevancy | Date

News Conference News AHA 2025

POLY-HF: Polypill Pays Dividends in Patients With HFrEF

Todd Neale

November 14, 2025

News Opinion Editor's Corner AHA 2025

What’s Going to Be Hot at AHA 2025?

Michael O'Riordan

November 05, 2025

News Conference News AHA 2024

Novel AI-Based, Noninvasive Sensor Can Accurately Measure PCWP in HFrEF

Yael L. Maxwell

November 25, 2024

News Conference News AHA 2024

Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression

Yael L. Maxwell

November 20, 2024

Presentation AHA 2024

Randomized Study Comparing PK/PD Properties of a Novel Intranasal Formulation of Bumetanide to Oral and IV Formulations

Presenter: Daniel Bensimhon

November 18, 2024

News Conference News AHA 2024

Nasal Bumetanide Safe, Effective in Healthy Adults

Yael L. Maxwell

November 18, 2024

News Conference News AHA 2024

Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY

Shelley Wood

November 17, 2024

Presentation AHA 2024

Novel AI to Assess Intracardiac Filling Pressure: The Non-invasive SEISMocardiogram In Cardiovascular Monitoring for Heart Failure I (SEISMIC-HF I) Study

Presenter: Liviu Klein

November 16, 2024

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

News Conference News AHA 2024

One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024

Shelley Wood

November 14, 2024

News Conference News AHA 2023

Seeing Sticker Price for HFrEF Meds Opens Door to Discussions

Caitlin E. Cox

November 14, 2023

News Conference News AHA 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

Shelley Wood

November 11, 2023

News Opinion Editor's Corner AHA 2023

What’s Going to Be Hot at AHA 2023

Shelley Wood

November 07, 2023

News Conference News AHA 2022

CRISPR/Cas-9 Gene Editing Shows Promise in Transthyretin Amyloidosis

Yael L. Maxwell

November 05, 2022

News Conference News AHA 2022

TRANSFORM-HF: Torsemide No Better Than Furosemide for Hospitalized HF

Todd Neale

November 05, 2022

News Conference News AHA 2022

Novel Intervention to Increase GDMT in HF Exploits Noncardiac Admissions

Yael L. Maxwell

November 01, 2022

News Conference News AHA 2021

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

Todd Neale

November 17, 2021

News Conference News AHA 2021

Canagliflozin Improves Quality of Life in HF Patients

Michael O'Riordan

November 16, 2021

News Conference News AHA 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

Shelley Wood

November 14, 2021

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Shelley Wood

November 08, 2021

Advertisement

POLY-HF: Polypill Pays Dividends in Patients With HFrEF

What’s Going to Be Hot at AHA 2025?

Novel AI-Based, Noninvasive Sensor Can Accurately Measure PCWP in HFrEF

Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression

Randomized Study Comparing PK/PD Properties of a Novel Intranasal Formulation of Bumetanide to Oral and IV Formulations

Nasal Bumetanide Safe, Effective in Healthy Adults

Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY

Novel AI to Assess Intracardiac Filling Pressure: The Non-invasive SEISMocardiogram In Cardiovascular Monitoring for Heart Failure I (SEISMIC-HF I) Study

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024

Seeing Sticker Price for HFrEF Meds Opens Door to Discussions

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

What’s Going to Be Hot at AHA 2023

CRISPR/Cas-9 Gene Editing Shows Promise in Transthyretin Amyloidosis

TRANSFORM-HF: Torsemide No Better Than Furosemide for Hospitalized HF

Novel Intervention to Increase GDMT in HF Exploits Noncardiac Admissions

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

Canagliflozin Improves Quality of Life in HF Patients

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content